Literature DB >> 6817452

Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin.

F De Clerck, J M Van Nueten.   

Abstract

In vitro stimulation of washed rat platelets (2.5 X 10(10)/1) with thrombin (0.002 U/1) as well as their activation on de-endothelialized vascular preparations, produced a strong contraction of isolated rat caudal arteries. Pharmacodissection and specific measurements of various mediators (5-hydroxytryptamine, thromboxane B2, ATP) showed the platelet-mediated contraction to be mainly mediated by 5-hydroxytryptamine, either by its direct effect or through amplification of prostaglandin-effects at the level of the vessel or the platelets. Platelet-mediated vasospastic episodes were effectively reduced by ketanserin, a selective 5-HT2 receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6817452     DOI: 10.1016/0049-3848(82)90009-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  12 in total

1.  Expression of 5-HT2A and 5-HT1B receptor mRNA in blood vessels.

Authors:  S Kato; H Kumamoto; M Hirano; H Akiyama; N Kaneko
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

2.  The effects of a selective 5-HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers.

Authors:  D S Millson; C L Jessup; A Swaisland; S Haworth; A Rushton; J D Harry
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

3.  The effects of a 5-HT2 receptor antagonist (ICI 169,369) on changes in waking EEG, pupillary responses and state of arousal in human volunteers.

Authors:  D S Millson; S J Haworth; A Rushton; D Wilkinson; S Hobson; J Harry
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 4.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

5.  Hyperreactivity of platelets to serotonin (5-hydroxytryptamine) in patients with cardiovascular diseases. Influence of ketanserin, a serotonin S2-receptor antagonist.

Authors:  J De Crée; V Roels; H Verhaegen
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Serotonin antagonists and vascular protection.

Authors:  A E Doyle
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

Review 7.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

8.  Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine.

Authors:  F De Clerck; Y Somers; L Van Gorp
Journal:  Agents Actions       Date:  1984-12

9.  Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.

Authors:  F De Clerck; B Xhonneux
Journal:  Agents Actions       Date:  1986-03

10.  The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.

Authors:  J De Cree; J Leempoels; B Demoen; V Roels; H Verhaegen
Journal:  Agents Actions       Date:  1985-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.